Non Receptor Tyrosine Protein Kinase TYK2 TYK2 or EC 2.7.10.2 Pipeline Review, H1 2018
Summary
Non Receptor Tyrosine Protein Kinase TYK2 TYK2 or EC 2.7.10.2 pipeline Target constitutes close to 19 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes. The latest report Non Receptor Tyrosine Protein Kinase TYK2 Pipeline Review, H1 2018, outlays comprehensive information on the Non Receptor Tyrosine Protein Kinase TYK2 TYK2 or EC 2.7.10.2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.
Non Receptor Tyrosine Protein Kinase TYK2 TYK2 or EC 2.7.10.2 Nonreceptor tyrosineprotein kinase TYK2 is an enzyme encoded by the TYK2 gene. It is involved in intracellular signal transduction by involving in the initiation of type I IFN signaling. It phosphorylates the interferonalpha/beta receptor alpha chain. It plays an import role in inflammation. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 3, 9 and 3 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Gastrointestinal, Oncology, Central Nervous System, Dermatology, Musculoskeletal Disorders and Undisclosed which include indications Ulcerative Colitis, Psoriasis, Autoimmune Disorders, Inflammation, Inflammatory Bowel Disease, Acute Lymphocytic Leukemia ALL, Acute Lymphoblastic Leukemia, Crohn's Disease Regional Enteritis, Multiple Sclerosis, Plaque Psoriasis Psoriasis Vulgaris, Rheumatoid Arthritis, Alopecia, Arthritis, BCell Chronic Lymphocytic Leukemia, BCell NonHodgkin Lymphoma, Cutaneous TCell Lymphoma, Diffuse Large BCell Lymphoma, Follicular Lymphoma, Hypersensitivity, Lupus Erythematosus, Lupus Nephritis, Mantle Cell Lymphoma, Marginal Zone Bcell Lymphoma, Peripheral TCell Lymphomas PTCL, Systemic Lupus Erythematosus, TCell Leukemia, Unspecified and Waldenstrom Macroglobulinemia.
Furthermore, this report also reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 TYK2 or EC 2.7.10.2 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Non Receptor Tyrosine Protein Kinase TYK2 TYK2 or EC 2.7.10.2
The report reviews Non Receptor Tyrosine Protein Kinase TYK2 TYK2 or EC 2.7.10.2 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 TYK2 or EC 2.7.10.2 targeted therapeutics and enlists all their major and minor projects
The report assesses Non Receptor Tyrosine Protein Kinase TYK2 TYK2 or EC 2.7.10.2 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Non Receptor Tyrosine Protein Kinase TYK2 TYK2 or EC 2.7.10.2 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Non Receptor Tyrosine Protein Kinase TYK2 TYK2 or EC 2.7.10.2
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Non Receptor Tyrosine Protein Kinase TYK2 TYK2 or EC 2.7.10.2 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Original Article: Non Receptor Tyrosine Protein Kinase TYK2 TYK2 or EC 2.7.10.2 Pipeline Review, H1 2018 [Report Updated: 27022018] Prices from USD $3500